DOI: 10.1055/s-00000142

Frauenheilkunde up2date

References

Ismael G, Hegg R, Muehlbauer S et al.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

Lancet Oncology 2012;
13: 869-878

Download Bibliographical Data

Access: